ONCE Spark Therapeutics, Inc.

54.12
+1  (2%)
Previous Close 52.95
Open 53.20
Price To book 4.95
Market Cap 1.68B
Shares 31,044,000
Volume 114,095
Short Ratio 12.66
Av. Daily Volume 289,768

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2016 with initial data due mid 2017.
SPK-8011
Hemophilia A
Phase 1/2 updated data at ASH 2016. Further update released April 6, 2017.
SPK-9001
Hemophilia B
Phase 1/2 dosing commenced 1Q 2015. Initial data due early 2017. Possibly at ARVO May 7-11, 2017 (not confirmed by company)
SPK-7001 (SPK-CHM)
Choroideremia
BLA filing due early 2017.
SPK-RPE65
Inherited retinal dystrophies

Latest News

  1. Mystery Clot Reveals a Helpful Mutant Gene in Hunt for a Cure
  2. ETFs with exposure to Spark Therapeutics, Inc. : April 7, 2017
  3. Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium
  4. Just How Much Is a Medical Miracle Worth?
  5. Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium
  6. ETFs with exposure to Spark Therapeutics, Inc. : March 27, 2017
  7. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  8. 3 Biotech Stocks to Buy in March
  9. 5 Small-Cap Biotech Stocks to Buy in March
  10. Spark Therapeutics to Participate in Multiple Conferences in March
  11. Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency
  12. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: 2016 By the Numbers : February 24, 2017
  13. Edited Transcript of ONCE earnings conference call or presentation 22-Feb-17 1:30pm GMT
  14. Why Spark's CEO says 2017 may be a 'historic year' for his gene therapy company
  15. Spark Therapeutics Reports 2016 Financial Results and Business Highlights
  16. Spark Therapeutics to Host Conference Call on Wednesday, Feb. 22 at 8:30 a.m. to Discuss 2016 Results
  17. Spark Therapeutics to Participate in Multiple February Conferences
  18. Spark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : January 18, 2017
  19. Spark Gets A Check From Pfizer And A Downgrade From Vetr